首页 > 最新文献

Medical Journal of Australia最新文献

英文 中文
The New South Wales Pharmacy Trial for herpes zoster: on the nose? 治疗带状疱疹的新南威尔士药房试验:在鼻子上?
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-13 DOI: 10.5694/mja2.52531
Christian P Pappas, Timothy R Holmes, Minas T Coroneo
<p><span>To the Editor:</span> Pharmacist prescribing initiatives in Australia are experiencing unprecedented popularity among state law makers, while community concerns regarding access to affordable general practice are increasing. Following the statewide roll-out of pharmacist prescribing for uncomplicated urinary tract infections among female patients aged 18–65 years, the New South Wales Pharmacy Trial continues to expand.<span><sup>1</sup></span> From 19 July 2024, participating pharmacists are authorised to assess and treat adults with common dermatological conditions, including herpes zoster (shingles), atopic dermatitis, impetigo, and plaque psoriasis, after undertaking a series of training modules.<span><sup>2</sup></span> The trial closes in February 2025, or when the maximum number of trial-supported consultations has been reached.<span><sup>2</sup></span> A similar 12-month pilot is currently underway in Victoria.<span><sup>3</sup></span></p><p>Although protocolised health care can prevent deviations from evidence-based care, robust clinical standards are required. The NSW trial's clinical practice guidelines for herpes zoster appropriately identify indications for immediate referral to a general practitioner or emergency department in the presence of complications, including postherpetic neuralgia, herpes zoster ophthalmicus, herpes zoster meningoencephalitis, and herpes zoster oticus (Ramsay Hunt syndrome). Despite correctly noting that “vesicles on the nose have been found to be predictive of eye involvement,” the guidelines erroneously attribute these findings (Hutchinson sign) to herpes zoster oticus, not herpes zoster ophthalmicus.<span><sup>4, 5</sup></span></p><p>Eponymously named for the English surgeon and ophthalmologist Sir Jonathan Hutchinson in 1864,<span><sup>6</sup></span> Hutchinson sign denotes cutaneous involvement of the lateral dorsum, tip or root of the nose. Attributed to varicella zoster virus reactivation within the infratrochlear and external nasal nerves, terminal divisions of the nasociliary nerve and ophthalmic nerve, Hutchinson sign strongly suggests a diagnosis of herpes zoster ophthalmicus.<span><sup>7</sup></span> It is a powerful predictor of varicella zoster virus keratitis, uveitis, and corneal denervation,<span><sup>8</sup></span> and is often taken by general practitioners as an indication for prompt ophthalmic referral.<span><sup>9</sup></span> In contrast, Ramsay Hunt syndrome is characterised by viral re-activation within the geniculate ganglion and is associated with ipsilateral otalgia, hearing loss, peripheral facial nerve palsy, and herpetiform rash within the external auditory canal, pinna, and oral mucosa.<span><sup>10</sup></span> The current clinical practice guidelines risk misdiagnosis between two anatomically distinct entities, with potential consequences, including inappropriate patient referral and delayed treatment initiation, which would not serve to allay community concerns reg
致编辑:澳大利亚的药剂师处方倡议在州立法者中前所未有地受到欢迎,而社区对获得负担得起的全科医生的关注正在增加。随着18-65岁女性患者无并发症尿路感染的药剂师处方在全州范围内的推广,新南威尔士州药房试验继续扩大从2024年7月19日起,参与的药剂师在接受一系列培训模块后,被授权评估和治疗患有常见皮肤病的成年人,包括带状疱疹(带状疱疹)、特应性皮炎、脓疱疮和斑块性牛皮癣试验将于2025年2月或达到试验支持咨询的最大数量时结束维多利亚州目前正在进行一项类似的为期12个月的试点。3尽管协议化的医疗保健可以防止偏离循证护理,但需要健全的临床标准。新南威尔士州试验的带状疱疹临床实践指南适当地确定了在出现并发症时立即转诊给全科医生或急诊科的适应症,包括疱疹后神经痛、带状疱疹眼、带状疱疹脑膜脑炎和带状疱疹耳部(拉姆齐·亨特综合征)。尽管正确地指出“鼻子上的小泡已被发现可预测眼部受累”,但指南错误地将这些发现(哈钦森征)归因于带状疱疹耳,而不是带状疱疹眼。哈钦森征是以1864年英国外科医生和眼科医生乔纳森·哈钦森爵士的名字命名的,哈钦森征指的是外侧背、鼻尖或鼻根的皮肤受累。由于水痘带状疱疹病毒在耳蜗下神经和鼻外神经、鼻睫神经和眼神经的末梢分裂内再活化,Hutchinson征象强烈提示诊断为眼带状疱疹它是水痘带状疱疹病毒性角膜炎、葡萄膜炎和角膜失神经8的有力预测指标,通常被全科医生作为及时眼科转诊的指征9相比之下,Ramsay Hunt综合征的特征是膝状神经节内的病毒再激活,并伴有同侧耳痛、听力丧失、周围面神经麻痹和外耳道、耳廓和口腔粘膜内的疱疹样皮疹目前的临床实践指南存在两种解剖结构不同的实体之间误诊的风险,并有潜在的后果,包括不适当的患者转诊和延迟治疗开始,这将无助于减轻新南威尔士州社区对药剂师处方的担忧。这一关切已于2024年9月25日传达给试验调查人员,供其进一步审查。无相关披露。
{"title":"The New South Wales Pharmacy Trial for herpes zoster: on the nose?","authors":"Christian P Pappas,&nbsp;Timothy R Holmes,&nbsp;Minas T Coroneo","doi":"10.5694/mja2.52531","DOIUrl":"10.5694/mja2.52531","url":null,"abstract":"&lt;p&gt;&lt;span&gt;To the Editor:&lt;/span&gt; Pharmacist prescribing initiatives in Australia are experiencing unprecedented popularity among state law makers, while community concerns regarding access to affordable general practice are increasing. Following the statewide roll-out of pharmacist prescribing for uncomplicated urinary tract infections among female patients aged 18–65 years, the New South Wales Pharmacy Trial continues to expand.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; From 19 July 2024, participating pharmacists are authorised to assess and treat adults with common dermatological conditions, including herpes zoster (shingles), atopic dermatitis, impetigo, and plaque psoriasis, after undertaking a series of training modules.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The trial closes in February 2025, or when the maximum number of trial-supported consultations has been reached.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; A similar 12-month pilot is currently underway in Victoria.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Although protocolised health care can prevent deviations from evidence-based care, robust clinical standards are required. The NSW trial's clinical practice guidelines for herpes zoster appropriately identify indications for immediate referral to a general practitioner or emergency department in the presence of complications, including postherpetic neuralgia, herpes zoster ophthalmicus, herpes zoster meningoencephalitis, and herpes zoster oticus (Ramsay Hunt syndrome). Despite correctly noting that “vesicles on the nose have been found to be predictive of eye involvement,” the guidelines erroneously attribute these findings (Hutchinson sign) to herpes zoster oticus, not herpes zoster ophthalmicus.&lt;span&gt;&lt;sup&gt;4, 5&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Eponymously named for the English surgeon and ophthalmologist Sir Jonathan Hutchinson in 1864,&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; Hutchinson sign denotes cutaneous involvement of the lateral dorsum, tip or root of the nose. Attributed to varicella zoster virus reactivation within the infratrochlear and external nasal nerves, terminal divisions of the nasociliary nerve and ophthalmic nerve, Hutchinson sign strongly suggests a diagnosis of herpes zoster ophthalmicus.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; It is a powerful predictor of varicella zoster virus keratitis, uveitis, and corneal denervation,&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; and is often taken by general practitioners as an indication for prompt ophthalmic referral.&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; In contrast, Ramsay Hunt syndrome is characterised by viral re-activation within the geniculate ganglion and is associated with ipsilateral otalgia, hearing loss, peripheral facial nerve palsy, and herpetiform rash within the external auditory canal, pinna, and oral mucosa.&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt; The current clinical practice guidelines risk misdiagnosis between two anatomically distinct entities, with potential consequences, including inappropriate patient referral and delayed treatment initiation, which would not serve to allay community concerns reg","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 11","pages":"632"},"PeriodicalIF":6.7,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52531","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Participation in the National Bowel Cancer Screening Program by people with severe mental illness, Australia, 2006–2019: a national data linkage study 2006-2019年澳大利亚重性精神病患者参与全国肠癌筛查计划的情况:一项全国数据链接研究。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-13 DOI: 10.5694/mja2.52521
Steve Kisely, Rebecca Seth, Susan J Jordan, Bradley Kendall, Dan J Siskind, Grant Sara, Justin Chapman, Lisa Brophy, David M Lawrence
<div> <section> <h3> Objective</h3> <p>To compare rates of participation in the National Bowel Cancer Screening Program (NBCSP) and follow-up for people with severe mental illness with those for people without severe mental illness or not prescribed antidepressants.</p> </section> <section> <h3> Study design</h3> <p>Retrospective cohort study; analysis of de-identified linked NBCSP, Pharmaceutical Benefits Scheme (PBS), and Medicare Benefits Schedule (MBS) data.</p> </section> <section> <h3> Setting</h3> <p>Australia, 2006–2019.</p> </section> <section> <h3> Participants</h3> <p>People aged 50–74 years (NBCSP-eligible) with severe mental illness, defined as those dispensed two or more prescriptions for second generation antipsychotics or for lithium (PBS data), and a random sample of people aged 50–74 years eligible for Medicare-subsidised services but never prescribed psychotropic medications (antipsychotics, lithium, antidepressants).</p> </section> <section> <h3> Main outcome measures</h3> <p>NBCSP participation (returned faecal occult blood test sample), valid test result, positive test result, and follow-up colonoscopy rates.</p> </section> <section> <h3> Results</h3> <p>A total of 119 475 people with severe mental illness and 1 090 574 control group people were included in our analyses. The proportion of women was larger in the severe mental illness group (51.3%) than the control group (48.7%), as were the proportions who lived in inner regional areas (23.5% <i>v</i> 19.1%) or in areas in the lowest socio-economic quintile (21.8% <i>v</i> 14.7%). The NBCSP participation rate was lower among people with severe mental illness (adjusted incidence rate ratio [IRR], 0.70; 95% confidence interval [CI], 0.69–0.84). The proportion of valid test results was smaller for people with severe mental illness (95.9% <i>v</i> 98.7%; adjusted IRR, 0.97; 95% CI, 0.96–0.99), and the positive test result proportion larger (12.3% <i>v</i> 6.6%; adjusted IRR, 2.01; 95% CI, 1.94–2.09). The proportion of positive test results followed by colonoscopy was smaller for people with severe mental illness (71.7% <i>v</i> 82.6%; adjusted IRR, 0.88; 95% CI, 0.85–0.92).</p> </section> <section> <h3> Conclusions</h3> <p>People with severe mental illness were less likely to part
研究目的比较重性精神病患者与非重性精神病患者或未服用抗抑郁药的患者参与国家肠癌筛查计划(NBCSP)的比例和随访情况:研究设计:回顾性队列研究;分析去标识化的关联NBCSP、药品福利计划(PBS)和医疗保险福利表(MBS)数据:澳大利亚,2006-2019年:年龄在 50-74 岁之间(符合 NBCSP 条件)的重性精神病患者,定义为开具过两次或两次以上第二代抗精神病药物处方或锂剂处方的患者(PBS 数据),以及随机抽样的年龄在 50-74 岁之间、符合 Medicare 补贴服务条件但从未开具过精神药物(抗精神病药物、锂剂、抗抑郁药)的患者:主要结果测量指标:NBCSP参与率(返回的粪便隐血试验样本)、有效试验结果、阳性试验结果和后续结肠镜检查率:共有 119 475 名重症精神病患者和 1 090 574 名对照组患者参与了我们的分析。重症精神病患者中女性的比例(51.3%)高于对照组(48.7%),居住在内城地区(23.5% 对 19.1%)或社会经济地位最低的五分之一地区(21.8% 对 14.7%)的女性比例也高于对照组。严重精神病患者的 NBCSP 参与率较低(调整后的发病率比 [IRR] 为 0.70;95% 置信区间 [CI],0.69-0.84)。重度精神病患者的有效检测结果比例较低(95.9% 对 98.7%;调整后的发生率比为 0.97;95% 置信区间为 0.96-0.99),阳性检测结果比例较高(12.3% 对 6.6%;调整后的发生率比为 2.01;95% 置信区间为 1.94-2.09)。重度精神病患者在检测结果呈阳性后再进行结肠镜检查的比例较小(71.7% 对 82.6%;调整后的 IRR,0.88;95% CI,0.85-0.92):结论:与其他澳大利亚人相比,患有严重精神疾病的人参加NBCSP或在检测结果呈阳性后接受结肠镜检查的可能性较低。这些差异可能是导致严重精神病患者结直肠癌死亡率较高的原因。至于癌症诊断阶段和后续治疗的差异对结肠直肠癌死亡率升高的影响,还需要进一步研究。
{"title":"Participation in the National Bowel Cancer Screening Program by people with severe mental illness, Australia, 2006–2019: a national data linkage study","authors":"Steve Kisely,&nbsp;Rebecca Seth,&nbsp;Susan J Jordan,&nbsp;Bradley Kendall,&nbsp;Dan J Siskind,&nbsp;Grant Sara,&nbsp;Justin Chapman,&nbsp;Lisa Brophy,&nbsp;David M Lawrence","doi":"10.5694/mja2.52521","DOIUrl":"10.5694/mja2.52521","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To compare rates of participation in the National Bowel Cancer Screening Program (NBCSP) and follow-up for people with severe mental illness with those for people without severe mental illness or not prescribed antidepressants.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Study design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Retrospective cohort study; analysis of de-identified linked NBCSP, Pharmaceutical Benefits Scheme (PBS), and Medicare Benefits Schedule (MBS) data.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Australia, 2006–2019.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Participants&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;People aged 50–74 years (NBCSP-eligible) with severe mental illness, defined as those dispensed two or more prescriptions for second generation antipsychotics or for lithium (PBS data), and a random sample of people aged 50–74 years eligible for Medicare-subsidised services but never prescribed psychotropic medications (antipsychotics, lithium, antidepressants).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main outcome measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;NBCSP participation (returned faecal occult blood test sample), valid test result, positive test result, and follow-up colonoscopy rates.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 119 475 people with severe mental illness and 1 090 574 control group people were included in our analyses. The proportion of women was larger in the severe mental illness group (51.3%) than the control group (48.7%), as were the proportions who lived in inner regional areas (23.5% &lt;i&gt;v&lt;/i&gt; 19.1%) or in areas in the lowest socio-economic quintile (21.8% &lt;i&gt;v&lt;/i&gt; 14.7%). The NBCSP participation rate was lower among people with severe mental illness (adjusted incidence rate ratio [IRR], 0.70; 95% confidence interval [CI], 0.69–0.84). The proportion of valid test results was smaller for people with severe mental illness (95.9% &lt;i&gt;v&lt;/i&gt; 98.7%; adjusted IRR, 0.97; 95% CI, 0.96–0.99), and the positive test result proportion larger (12.3% &lt;i&gt;v&lt;/i&gt; 6.6%; adjusted IRR, 2.01; 95% CI, 1.94–2.09). The proportion of positive test results followed by colonoscopy was smaller for people with severe mental illness (71.7% &lt;i&gt;v&lt;/i&gt; 82.6%; adjusted IRR, 0.88; 95% CI, 0.85–0.92).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;People with severe mental illness were less likely to part","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 11","pages":"617-622"},"PeriodicalIF":6.7,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11625528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decolonisation, Indigenous health research and Indigenous authorship: sharing our teams’ principles and practices 非殖民化、土著健康研究和土著作者身份:分享我们团队的原则和实践。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-11 DOI: 10.5694/mja2.52509
Pat Dudgeon (Bardi), Helen Milroy (Palyku), Belle Selkirk (Noongar), Ashleigh Wright (Nunga), Kahli Regan (Wongi and Noongar), Shraddha Kashyap, Rama Agung-Igusti, Joanna Alexi, Abigail Bray, Joan Chan, Ee Pin Chang, Sze Wing Georgiana Cheuk, Jemma Collova, Kate Derry, Chontel Gibson (Gamilaraay)
<p>The authorship order for this article was led by and decided by Pat Dudgeon and Helen Milroy, based on work conducted within and reported by the team. Before that decision, each team member was provided an opportunity to write a summary of their contributions to the article, as well as recognise other authors’ roles and responsibilities in the process. The authors’ contributions, as per the CRediT for this article are as follows, noting that only the relevant roles from CRediT are included: Conceptualisation: Pat Dudgeon (PD) and Helen Milroy (HM) provided leadership for the development and application of Indigenous authorship principles, including holding space for conversations and activities to support the learning within the team. The remaining authors learn, practice and support the application of Indigenous authorship principles. Chontel Gibson (CG) and Shraddha Kashyap (SK) led the conceptualisation of the article in consultation with the remaining authors. Methodology: CG led the methodological approach to design and write the article. HM and PD provided leadership and advice. Supervision: CG and SK provided everyday supervision and guidance to draft the article. PD and HM provided strategic oversight. Project administration: CG and SK led the administration aspects of this article, including discussions and development. Writing – original draft: led by CG and SK with strategic oversight by PD and HM. Various support provided by the remaining authors. Writing – reviewing and editing: led by CG, Ashleigh Wright, Jemma Rose Collova and Rama Agung-Igusti, with strategic advice, and review by PD and HM. Various support provided by the remaining authors.</p><p>Indigenous relationality is a shared principle that is practiced by Indigenous peoples across the world.<span><sup>1, 2</sup></span> It requires people to share cultural connections, along with intentions. In this article, we illustrate our positionality by using a similar approach to Bullen and colleagues.<span><sup>3</sup></span></p><p>Aboriginal and Torres Strait Islander peoples’ knowledges and practices are grounded in the principles of relationality, which are foundational for flourishing communities.<span><sup>3</sup></span> The historical and contemporary legacies of colonisation remain in everyday practices. These colonial legacies are a product of and result in racism, whereby there are deliberate attempts and/or everyday practices that destroy Indigenous Knowledges, such as languages, principles of relationality and cultural practices.<span><sup>12, 13</sup></span> Western research paradigms, which are grounded in colonial ideology, have played a significant role in that destruction. Western researchers, the academy and disciplines produced within the academy, are contexts that position non-Indigenous people, along with their processes and systems, as being the “knower” of Indigenous peoples, including Indigenous Knowledges. Within these same colonial research systems, Indi
这篇文章的作者顺序是由Pat Dudgeon和Helen Milroy领导和决定的,基于团队内部进行的工作和报告。在做出决定之前,每个团队成员都有机会撰写他们对文章的贡献摘要,并认识到其他作者在此过程中的角色和责任。根据本文的信用,作者的贡献如下,注意仅包括信用中的相关角色:概念化:Pat Dudgeon (PD)和Helen Milroy (HM)为土著作者原则的发展和应用提供了领导,包括为对话和活动提供空间,以支持团队内部的学习。其余的作者学习、实践和支持土著作者原则的应用。Chontel Gibson (CG)和Shraddha Kashyap (SK)与其他作者协商,领导了文章的概念化。方法论:CG主导了设计和撰写文章的方法论方法。HM和PD提供了领导和建议。监督:CG和SK对文章的起草进行日常监督和指导。PD和HM提供战略监督。项目管理:CG和SK领导了本文的管理方面,包括讨论和开发。写作-初稿:由CG和SK主导,PD和HM负责战略监督。其他作者提供的各种支持。写作-审查和编辑:由CG, Ashleigh Wright, Jemma Rose Collova和Rama Agung-Igusti领导,提供战略建议,并由PD和HM审查。其他作者提供的各种支持。土著关系是世界各地土著人民奉行的一项共同原则。1,2它要求人们分享文化联系,以及意图。在这篇文章中,我们通过使用与布伦和同事类似的方法来说明我们的立场。3 .土著人和托雷斯海峡岛民的知识和做法是以关系原则为基础的,而关系原则是社区繁荣的基础殖民的历史和当代遗产仍然存在于日常实践中。这些殖民遗产是种族主义的产物和结果,因此有蓄意的企图和/或日常的做法破坏土著知识,如语言、关系原则和文化习俗。12,13以殖民意识形态为基础的西方研究范式在这种破坏中发挥了重要作用。西方研究人员、学院和学院内产生的学科是将非土著人民及其过程和系统定位为土著人民包括土著知识的“知者”的背景。在同样的殖民研究体系中,土著人民被视为有待了解的对象,土著知识被视为一种商品,为了西方社会的利益,通过西方的视角被提取、贬值和重新连接尽管在这种背景下,土著和托雷斯海峡岛民继续抵制、倡导和领导维持、恢复或重建土著知识的解决办法。13-16自决和自治是土著人民抵抗、宣传和领导的核心。他们也是土著保护、生产、拥有和传播土著知识的核心。1,12,13,17土著人民领导土著权利运动,包括土著知识和实践自决的许多重要例子之一是通过《联合国土著人民权利宣言》(《宣言》)和《联合国土著人民权利宣言社区指南》(《社区指南》)。11,18联合国开发计划署承认并尊重土著人民“维持、控制、保护和发展”其知识体系的个人和集体权利,以及“对这种文化遗产、传统知识和传统文化表现形式的知识产权”在改革包括学院在内的殖民机构的进程中,《方案》所主张的权利是根本和基础的。《社区指南》全面说明了如何在土著和托雷斯海峡岛民中执行方案认识正义,即承认土著人民(和所有人)拥有重要的知识,是任何基于土著权利的方法的核心土著人权不仅承认土著人民拥有重要的知识,而且主张土著人民是合法的所有者,他们应该保持领导、治理和与土著知识的联系。17,18殖民源于并延续了知识、知识生产和知识实践的种族不平衡。 非殖民化和非殖民化是企图拆除、阻碍、扭转、停止或消除殖民做法的许多工具中的几个,其目的是使土著人民的权利享有特权。13、20-22我们承认非殖民化和非殖民化实践的各种概念和应用,有时是相互冲突的。这些冲突受到地方、人民和社会政治背景的影响,包括缺乏有利于土著人民的变革行动。21,23 -26以下描述了我们在团队中实施的与非殖民化和非殖民化实践有关的许多关键特征中的三个。要参与土著健康研究,首先必须了解存在着各种各样的土著知识。在本文中,我们将土著知识视为包括文化知识(过去和现在)、土著人民的生活经验,以及有时可能结合西方和土著知识的新知识。我们承认生活经验的多样性,并使用各种反映和建立在土著知识基础上的创新概念工具,例如Milroy的“生命之舞”,以及Gee及其同事的SEWB模型,这些都是我们工作的基础。28,29土著知识反映在对健康、福祉和生活采取的整体办法中。整体方法包括与文化、精神、社会和健康有关的多种知识,所有这些知识都建立在国家和爱的故事、科学和实践中。Zubrzycki及其同事引用的Yunkaporta提供了一系列与土著和托雷斯海峡岛民知识接触的文化协议。文化协议的例子包括使用文化过程,如编织、故事和艺术,与土著和托雷斯海峡岛民的知识相结合;了解自己的定位;解决自己的恐惧和不适,最后,确保土著和托雷斯海峡岛民知识的任何使用都有利于土著和托雷斯海峡岛民社区。文化规范也存在于研究过程中。原住民参与行动研究(APAR)说明了与社会和情感健康相关的研究中使用的文化协议。APAR重视原住民和托雷斯海峡岛民的知识它提供了一种非殖民化和基于权利的土著研究方法。APAR的主要内容集中在本地知识的产生以及土著和托雷斯海峡岛民作为共同研究人员;土著人民根据自身健康、家庭和社区的经验成为专家;土著领导和治理、研究翻译和传播,为当地社区量身定制;土著伦理实践的应用,最后,实施斯旺和拉斐尔的九项指导原则,这些原则支撑着sew。史密斯观察到,过去二十年导致了土著研究的快速增长同样,SEWB文献综述揭示了大量由土著和托雷斯海峡岛民领导和管理的研究(未发表的数据)。土著研究的扩大说明了土著人民的知识和实践如何能够在学院内超越和制定土著人权。尽管本土知识超越了学术界,史密斯认为西方学科和机构仍然难以承认本土知识的贡献。13缺乏承认可以在西方学科和研究人员的引用模式中得到证明,这些模式经常排斥或低估种族化的学者土著知识的缺乏还表现在教育项目中教授的土著内容数量有限等挑战;学院中确定的土著职位数量有限,进入文化上安全的机构(例如大学课程和保健服务)的机会有限,这阻碍了土著人民作为消费者、工作人员和学生等利用这些机构。8,21,34,35这些问题是埃默里-惠廷顿所说的殖民压迫的持续传播所造成的我们承认为减轻殖民压迫的传播作出了努力例如,虽然许多土著社区控制的组织实施了土著和托雷斯海峡岛民的社会和情感健康,但主流卫生组织的吸收并不明显(未公布的数据)。土著人民是土著知识的合法拥有者,在研究过程中,土著作者身份是实现这一权利的一种机制。土著出版商长期以来一直主张土著作者。 例如,《土著和托雷斯海峡岛民作者的道德出版指南》和来自这些社区的研究说明了澳大利亚版权法的问题,因为它们将所有权授予记录土著知识的人,而不是土著知识的合法所有者。Janke38强调版权法和知识产权规则如何使经常从法律和规则中受益的非土著人民享有特权。特别是涉及到土著人民时。期刊越来越意识到它们在出版过程中促进土著作者身份的责任。39,40学术文章现在揭示了指导方针、工具和清单,以支持土著作者的过程。例如,Kennedy及其同事说明了土著作者身份的重要性,强调在使用土著方法/方法学时,将土著作者置于作者身份顺序的第一位和最后一位的优点CAVAL和土著档案集体指南及其土著知识归因工具包是为本科生设计的42 .这些资源的目的是支持学生选择以实力为基础并包含土著领导的参考资料,包括土著作者
{"title":"Decolonisation, Indigenous health research and Indigenous authorship: sharing our teams’ principles and practices","authors":"Pat Dudgeon (Bardi),&nbsp;Helen Milroy (Palyku),&nbsp;Belle Selkirk (Noongar),&nbsp;Ashleigh Wright (Nunga),&nbsp;Kahli Regan (Wongi and Noongar),&nbsp;Shraddha Kashyap,&nbsp;Rama Agung-Igusti,&nbsp;Joanna Alexi,&nbsp;Abigail Bray,&nbsp;Joan Chan,&nbsp;Ee Pin Chang,&nbsp;Sze Wing Georgiana Cheuk,&nbsp;Jemma Collova,&nbsp;Kate Derry,&nbsp;Chontel Gibson (Gamilaraay)","doi":"10.5694/mja2.52509","DOIUrl":"10.5694/mja2.52509","url":null,"abstract":"&lt;p&gt;The authorship order for this article was led by and decided by Pat Dudgeon and Helen Milroy, based on work conducted within and reported by the team. Before that decision, each team member was provided an opportunity to write a summary of their contributions to the article, as well as recognise other authors’ roles and responsibilities in the process. The authors’ contributions, as per the CRediT for this article are as follows, noting that only the relevant roles from CRediT are included: Conceptualisation: Pat Dudgeon (PD) and Helen Milroy (HM) provided leadership for the development and application of Indigenous authorship principles, including holding space for conversations and activities to support the learning within the team. The remaining authors learn, practice and support the application of Indigenous authorship principles. Chontel Gibson (CG) and Shraddha Kashyap (SK) led the conceptualisation of the article in consultation with the remaining authors. Methodology: CG led the methodological approach to design and write the article. HM and PD provided leadership and advice. Supervision: CG and SK provided everyday supervision and guidance to draft the article. PD and HM provided strategic oversight. Project administration: CG and SK led the administration aspects of this article, including discussions and development. Writing – original draft: led by CG and SK with strategic oversight by PD and HM. Various support provided by the remaining authors. Writing – reviewing and editing: led by CG, Ashleigh Wright, Jemma Rose Collova and Rama Agung-Igusti, with strategic advice, and review by PD and HM. Various support provided by the remaining authors.&lt;/p&gt;&lt;p&gt;Indigenous relationality is a shared principle that is practiced by Indigenous peoples across the world.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; It requires people to share cultural connections, along with intentions. In this article, we illustrate our positionality by using a similar approach to Bullen and colleagues.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Aboriginal and Torres Strait Islander peoples’ knowledges and practices are grounded in the principles of relationality, which are foundational for flourishing communities.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; The historical and contemporary legacies of colonisation remain in everyday practices. These colonial legacies are a product of and result in racism, whereby there are deliberate attempts and/or everyday practices that destroy Indigenous Knowledges, such as languages, principles of relationality and cultural practices.&lt;span&gt;&lt;sup&gt;12, 13&lt;/sup&gt;&lt;/span&gt; Western research paradigms, which are grounded in colonial ideology, have played a significant role in that destruction. Western researchers, the academy and disciplines produced within the academy, are contexts that position non-Indigenous people, along with their processes and systems, as being the “knower” of Indigenous peoples, including Indigenous Knowledges. Within these same colonial research systems, Indi","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 11","pages":"578-586"},"PeriodicalIF":6.7,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11625532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interventions for Aboriginal and Torres Strait Islander people with type 2 diabetes that modify its management and cardiometabolic risk factors: a systematic review 针对原住民和托雷斯海峡岛民 2 型糖尿病患者采取干预措施,以改变其管理和心脏代谢风险因素:系统性综述。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-10 DOI: 10.5694/mja2.52508
Ciying Tan, Zoe Williams, Mohammad Ashraful Islam, Ray Kelly, Tuguy Esgin, Elif I Ekinci
<div> <section> <h3> Objectives</h3> <p>To review studies of interventions for reducing the impact of type 2 diabetes in Aboriginal and Torres Strait Islander people. The primary aim was to review and summarise the characteristics and findings of the interventions. The secondary aims were to assess their effects on diabetes and cardiometabolic risk factors, and the proportions of people with type 2 diabetes who achieved therapeutic targets with each intervention.</p> </section> <section> <h3> Study design</h3> <p>We searched eight electronic databases for publications of studies including Aboriginal or Torres Strait Islander people aged 15 years or older with diagnoses of type 2 diabetes, describing one or more diabetes interventions, and published in English during 1 January 2000 – 31 December 2020. Reference lists in the assessed articles were checked for further relevant publications.</p> </section> <section> <h3> Data sources</h3> <p>MEDLINE (Ovid), Web of Science (Clarivate), the Cochrane Library, Global Health (EBSCO), Indigenous Collection and Indigenous Australia (Informit), Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the World Health Organization International Clinical Trials Registry Platform (WHO-ICTRP).</p> </section> <section> <h3> Results</h3> <p>The database searches yielded 1424 unique records; after screening by title and abstract, the full text of 55 potentially relevant articles were screened, of which seventeen met our eligibility criteria: eleven cohort studies (seven retrospective audits and four prospective studies), three randomised controlled trials, and three observational, non-randomised follow-up studies. Twelve publications reported site-based (Aboriginal or Torres Strait Islander health service or diabetes clinic) rather than individual-based diabetes interventions. Interventions with statistically significant effects on mean glycated haemoglobin (HbA<sub>1c</sub>) levels were laparoscopic adjustable gastric banding, a 5-day diabetes self-management camp, treatment of <i>Strongyloides stercoralis</i> infections, community-based health worker-led management, point-of-care testing, and self-management approaches.</p> </section> <section> <h3> Conclusions</h3> <p>Few interventions for Aboriginal and Torres Strait Islander people with type 2 diabetes have been reported in peer-reviewed publications. Improving diabetes care services resulted in larger proportions of people achieving therapeutic Hb
目的回顾有关减少 2 型糖尿病对土著居民和托雷斯海峡岛民影响的干预措施的研究。主要目的是回顾和总结干预措施的特点和结果。次要目的是评估干预措施对糖尿病和心脏代谢风险因素的影响,以及通过每种干预措施达到治疗目标的 2 型糖尿病患者的比例:我们在八个电子数据库中检索了 2000 年 1 月 1 日至 2020 年 12 月 31 日期间用英语发表的研究论文,其中包括年龄在 15 岁或以上、确诊为 2 型糖尿病的原住民或托雷斯海峡岛民,并介绍了一种或多种糖尿病干预措施。数据来源:MEDLINE(Ovid):数据来源:MEDLINE (Ovid)、Web of Science (Clarivate)、Cochrane Library、Global Health (EBSCO)、Indigenous Collection and Indigenous Australia (Informit)、Cumulative Index to Nursing and Allied Health Literature (CINAHL)、World Health Organization International Clinical Trials Registry Platform (WHO-ICTRP):通过数据库检索获得了 1424 条唯一记录;经过标题和摘要筛选后,筛选出 55 篇潜在相关文章的全文,其中 17 篇符合我们的资格标准:11 篇队列研究(7 篇回顾性审计和 4 篇前瞻性研究)、3 篇随机对照试验和 3 篇观察性非随机随访研究。有 12 篇文献报道了基于地点(原住民或托雷斯海峡岛民医疗服务机构或糖尿病诊所)而非个人的糖尿病干预措施。对平均糖化血红蛋白(HbA1c)水平有显著统计学影响的干预措施包括腹腔镜可调节胃束带术、为期5天的糖尿病自我管理营、治疗盘尾丝虫病感染、社区卫生工作者主导的管理、护理点检测以及自我管理方法:在同行评审的出版物中,针对土著居民和托雷斯海峡岛民 2 型糖尿病患者的干预措施鲜有报道。改善糖尿病护理服务可使更多患者达到治疗性 HbA1c 目标。当土著居民和托雷斯海峡岛民社区参与到干预措施的各个层面时,效果会更好。对整体性、文化安全性和可及性干预措施的高质量研究应成为研究重点。
{"title":"Interventions for Aboriginal and Torres Strait Islander people with type 2 diabetes that modify its management and cardiometabolic risk factors: a systematic review","authors":"Ciying Tan,&nbsp;Zoe Williams,&nbsp;Mohammad Ashraful Islam,&nbsp;Ray Kelly,&nbsp;Tuguy Esgin,&nbsp;Elif I Ekinci","doi":"10.5694/mja2.52508","DOIUrl":"10.5694/mja2.52508","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To review studies of interventions for reducing the impact of type 2 diabetes in Aboriginal and Torres Strait Islander people. The primary aim was to review and summarise the characteristics and findings of the interventions. The secondary aims were to assess their effects on diabetes and cardiometabolic risk factors, and the proportions of people with type 2 diabetes who achieved therapeutic targets with each intervention.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Study design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We searched eight electronic databases for publications of studies including Aboriginal or Torres Strait Islander people aged 15 years or older with diagnoses of type 2 diabetes, describing one or more diabetes interventions, and published in English during 1 January 2000 – 31 December 2020. Reference lists in the assessed articles were checked for further relevant publications.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Data sources&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;MEDLINE (Ovid), Web of Science (Clarivate), the Cochrane Library, Global Health (EBSCO), Indigenous Collection and Indigenous Australia (Informit), Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the World Health Organization International Clinical Trials Registry Platform (WHO-ICTRP).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The database searches yielded 1424 unique records; after screening by title and abstract, the full text of 55 potentially relevant articles were screened, of which seventeen met our eligibility criteria: eleven cohort studies (seven retrospective audits and four prospective studies), three randomised controlled trials, and three observational, non-randomised follow-up studies. Twelve publications reported site-based (Aboriginal or Torres Strait Islander health service or diabetes clinic) rather than individual-based diabetes interventions. Interventions with statistically significant effects on mean glycated haemoglobin (HbA&lt;sub&gt;1c&lt;/sub&gt;) levels were laparoscopic adjustable gastric banding, a 5-day diabetes self-management camp, treatment of &lt;i&gt;Strongyloides stercoralis&lt;/i&gt; infections, community-based health worker-led management, point-of-care testing, and self-management approaches.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Few interventions for Aboriginal and Torres Strait Islander people with type 2 diabetes have been reported in peer-reviewed publications. Improving diabetes care services resulted in larger proportions of people achieving therapeutic Hb","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 11","pages":"623-630"},"PeriodicalIF":6.7,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11625535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
“If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials "如果你建造了它,他们就会来":儿科脑癌临床试验中资金、研究与合作的融合。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-07 DOI: 10.5694/mja2.52506
Jordan Hansford, Santosh Valvi, Jasper de Boer, Geoff McCowage, Dinisha Govender, Maria Kirby, David Ziegler, Neevika Manoharan, Timothy Hassall, Brandon Wainwright, Frank Alvaro, Paul J Wood, David Eisenstat, Dong Anh Khuong Quang, Misty Jenkins, Matthew Dun, Stephen J Laughton, Raelene Endersby, Andrew Dodgshun, Nicholas Gottardo
<p>Each year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer. Despite paediatric cancer accounting for less than 1% of all cancer cases, the impact on their families and communities is profound and disproportionate.<span><sup>1-3</sup></span> Paediatric brain cancers are the most significant cause of cancer-related deaths within this age group, responsible for 40% of fatalities despite representing only 14% of diagnoses.<span><sup>2</sup></span> Although significant advances in paediatric cancer treatments have pushed overall cure rates above 80%, the outlook for many brain tumour types remains bleak.<span><sup>4</sup></span> Moreover, survivors often face lifelong clinical sequelae that severely diminish their quality of life,<span><sup>5</sup></span> with 60% of survivors unable to reach independence in adulthood.<span><sup>6</sup></span> This stark reality underscores the need for the expansion of clinical trials and integrated preclinical research aimed at improving outcomes for these individuals.</p><p>Conducting clinical trials in paediatric oncology faces many challenges, notably in regions with small populations spread across large geographic areas. Additional challenges include the rarity of each diagnosis, requiring international collaboration for patient accrual within feasible timelines.<span><sup>7-9</sup></span> The limited duration and availability of grant funding complicates this, as the time for patient accrual and the generation of meaningful outcome data often surpasses funding periods. The specificity of diagnoses and the need for complex, multi-agent therapies reduce the appeal of these trials to pharmaceutical companies, which favour single-drug therapies. This necessitates consistent funding to maintain a skilled workforce in clinical trial conduct and monitoring. In this context, the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) and the Australian Brain Cancer Mission (ABCM)<span><sup>10</sup></span> have been addressing these challenges. By strategically deploying funds and fostering collaborations, ABCM and ANZCHOG have tackled the barriers that hinder clinical trial execution. ABCM provides the financial support needed for partnerships and trial capacity enhancement. ANZCHOG leads in navigating the challenges of paediatric oncology trials, building a network that overcomes logistical and financial constraints to facilitate progress and discovery.</p><p>Initiated in 2017 with the targeted mission of enhancing brain cancer outcomes, the ABCM strategically mobilises resources, collaborations and research with the goal to double brain cancer survival rates.<span><sup>10</sup></span> This mission is supported by a detailed strategic framework, blending substantial financial backing with extensive stakeholder engagement and a co-funded model that unites government, philanthropic and private sectors. This strategy not only amplifies research fu
COZMOS评估了新的联合治疗方案,旨在提高侵袭性脑癌患儿的存活率,而INFORM2 NivEnt则开创了一种精准医疗方法,根据个体肿瘤的遗传特征量身定制治疗方案。ANZCHOG参与国际联盟的范围显著扩大,在与儿童肿瘤组织(COG)8和国际儿科肿瘤学会(SIOP)9等国际合作组织现有合作的基础上,又新增了6个合作伙伴关系(方框3)。这使得澳大利亚和新西兰的儿童能够参与更多的全球临床试验,尤其是创新性的早期试验。这种国际性确保了澳大拉西亚儿童肿瘤学始终处于全球研究工作的前沿,从该领域的世界性进展中获益并为之做出贡献。这些试验组合证明了澳大利亚中枢神经系统肿瘤研究组(ANZCHOG CNS Tumour Group)和澳大利亚中枢神经系统肿瘤协会(ABCM)的战略规划,强调了基础设施资金对执行复杂临床试验的至关重要性,并突出了国际合作在扩大研究范围和影响方面的重要作用。通过这些合作举措,参与临床试验的门槛大大降低,使更多人有机会获得创新治疗。18 尽管在 ABCM 和 ANZCHOG 中枢神经系统肿瘤小组的共同努力下,儿科脑癌临床试验取得了长足进步,但前进的道路上仍充满了操作和后勤方面的挑战。资源限制仍然是一个重大障碍,约 67% 的临床研究人员的资金来自外部非运营资源(ANZCHOG 数据),这凸显了对慈善事业和外部赠款的依赖性。资金的短暂性,以及相当一部分临床研究助理和临床研究护士的短期合同,加剧了招聘和留住人才的挑战,导致他们流向行业,阻碍了临床试验运营的灵活性和连续性。这些挑战突出表明,有必要在 ABCM 之外建立持续的战略性资助机制,以保持当前的发展势头。对多样化治疗方案的需求,特别是在标准治疗无法满足需求时对研究疗法的需求,凸显了持续增加研究和临床试验投资的重要性。这种承诺对于满足社区对临床试验的期望至关重要,尤其是对于预后具有挑战性的疾病,以确保家庭能够找到希望,而不必承受到国外寻求治疗的负担。在战略合作和定向资助的支持下,迄今为止所取得的成就为我们树立了榜样。要在此基础上再接再厉,就必须通过创新的资助模式、灵活的监管和加强国际合作伙伴关系来应对现有的挑战。我们的目标是创建一个持续资助的生态系统,不仅推动儿科脑癌研究,而且激励更广泛的儿科肿瘤学界采取类似举措。这一愿景既是美好的,也是可以实现的,持续的投资将成为临床试验成功新时代的催化剂,最终改变这些儿童和家庭的生活。
{"title":"“If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials","authors":"Jordan Hansford,&nbsp;Santosh Valvi,&nbsp;Jasper de Boer,&nbsp;Geoff McCowage,&nbsp;Dinisha Govender,&nbsp;Maria Kirby,&nbsp;David Ziegler,&nbsp;Neevika Manoharan,&nbsp;Timothy Hassall,&nbsp;Brandon Wainwright,&nbsp;Frank Alvaro,&nbsp;Paul J Wood,&nbsp;David Eisenstat,&nbsp;Dong Anh Khuong Quang,&nbsp;Misty Jenkins,&nbsp;Matthew Dun,&nbsp;Stephen J Laughton,&nbsp;Raelene Endersby,&nbsp;Andrew Dodgshun,&nbsp;Nicholas Gottardo","doi":"10.5694/mja2.52506","DOIUrl":"10.5694/mja2.52506","url":null,"abstract":"&lt;p&gt;Each year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer. Despite paediatric cancer accounting for less than 1% of all cancer cases, the impact on their families and communities is profound and disproportionate.&lt;span&gt;&lt;sup&gt;1-3&lt;/sup&gt;&lt;/span&gt; Paediatric brain cancers are the most significant cause of cancer-related deaths within this age group, responsible for 40% of fatalities despite representing only 14% of diagnoses.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Although significant advances in paediatric cancer treatments have pushed overall cure rates above 80%, the outlook for many brain tumour types remains bleak.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Moreover, survivors often face lifelong clinical sequelae that severely diminish their quality of life,&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; with 60% of survivors unable to reach independence in adulthood.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; This stark reality underscores the need for the expansion of clinical trials and integrated preclinical research aimed at improving outcomes for these individuals.&lt;/p&gt;&lt;p&gt;Conducting clinical trials in paediatric oncology faces many challenges, notably in regions with small populations spread across large geographic areas. Additional challenges include the rarity of each diagnosis, requiring international collaboration for patient accrual within feasible timelines.&lt;span&gt;&lt;sup&gt;7-9&lt;/sup&gt;&lt;/span&gt; The limited duration and availability of grant funding complicates this, as the time for patient accrual and the generation of meaningful outcome data often surpasses funding periods. The specificity of diagnoses and the need for complex, multi-agent therapies reduce the appeal of these trials to pharmaceutical companies, which favour single-drug therapies. This necessitates consistent funding to maintain a skilled workforce in clinical trial conduct and monitoring. In this context, the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) and the Australian Brain Cancer Mission (ABCM)&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt; have been addressing these challenges. By strategically deploying funds and fostering collaborations, ABCM and ANZCHOG have tackled the barriers that hinder clinical trial execution. ABCM provides the financial support needed for partnerships and trial capacity enhancement. ANZCHOG leads in navigating the challenges of paediatric oncology trials, building a network that overcomes logistical and financial constraints to facilitate progress and discovery.&lt;/p&gt;&lt;p&gt;Initiated in 2017 with the targeted mission of enhancing brain cancer outcomes, the ABCM strategically mobilises resources, collaborations and research with the goal to double brain cancer survival rates.&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt; This mission is supported by a detailed strategic framework, blending substantial financial backing with extensive stakeholder engagement and a co-funded model that unites government, philanthropic and private sectors. This strategy not only amplifies research fu","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 10","pages":"520-523"},"PeriodicalIF":6.7,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52506","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Defining the gap, emphasising the deficit 确定差距,强调不足。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-07 DOI: 10.5694/mja2.52518
Bridie Mulholland

To the Editor: The Australian National Agreement on Closing the Gap is an undeniably important piece of political infrastructure.1 The new approach, outlined in the 2020 National Agreement, vows to achieve First Nations equity by recognising the strength of, and empowering, First Nations people, communities and organisations.

By its nature, “closing the gap” inadvertently places non-Indigenous Australians above First Nations people and sets outcomes of non-Indigenous Australians as the gold standard. Although it is important to understand the relative and disproportionate disadvantage that First Nations people experience in Australia, the closing the gap narrative continues to perpetuate deficit discourse and encourages the benchmarking of First Nations outcomes against non-Indigenous Australians.

This deficit-driven process of benchmarking has become increasingly prevalent in First Nations-focused research, where the research problem is often described by the relative gap between First Nations people and non-Indigenous Australians. In many cases, highlighting the gap provides little value to the research, and only persists to promote deficit discourse — by continually defining the gap, we continually emphasise the deficit.

Progress towards equity for First Nations people has been slow, stunted and non-existent in many of the Closing the Gap target and priority reform areas.2 In light of this, the importance of moving away from the deficit narrative surrounding First Nations outcomes is being increasingly recognised.3 Driving high quality research in genuine partnership with First Nations people is key to driving real change. As such, it is critical that researchers, reviewers and journals play their part in shifting the deficit narrative.

Defining the research problem is integral to effective dissemination of research findings and attraction of funding. For health research, this often means defining rates of disease morbidity and mortality. These statistics are seldom positive but provide important context to research studies. Shifting the deficit narrative in First Nations health research should not mean that important, but negative, statistics are omitted from the story; rather, researchers should remain cognisant of the deficit narrative that comparison of First Nations outcomes to non-Indigenous Australians perpetuates, and should seek to only compare outcomes where it is absolutely pertinent to the context of the study.

No relevant disclosures.

致编辑:《澳大利亚缩小贫富差距全国协议》无疑是政治基础设施的重要组成部分2020年全国协议概述了新方法,承诺通过承认原住民、社区和组织的力量并赋予他们权力,实现原住民的平等。就其本质而言,“缩小差距”无意中将非土著澳大利亚人置于第一民族之上,并将非土著澳大利亚人的结果设定为黄金标准。虽然理解第一民族在澳大利亚经历的相对和不成比例的劣势很重要,但缩小差距的叙述继续使赤字话语永存,并鼓励将第一民族的结果与非土著澳大利亚人进行比较。这种赤字驱动的基准过程在以第一民族为重点的研究中变得越来越普遍,在这些研究问题中,第一民族和非土著澳大利亚人之间的相对差距经常被描述为第一民族的研究问题。在许多情况下,强调差距对研究没有什么价值,只会持续促进赤字话语——通过不断定义差距,我们不断强调赤字。在许多缩小差距目标和优先改革领域中,为土著人民争取平等的进展缓慢、受阻和不存在有鉴于此,越来越多的人认识到,摆脱围绕第一民族成果的赤字叙事的重要性与原住民建立真正的伙伴关系,推动高质量的研究,是推动真正变革的关键。因此,研究人员、审稿人和期刊在改变赤字叙事方面发挥自己的作用是至关重要的。界定研究问题是有效传播研究成果和吸引资金的必要条件。对于卫生研究,这通常意味着确定疾病发病率和死亡率。这些统计数据很少是积极的,但为研究提供了重要的背景。改变第一民族健康研究中的赤字叙述不应该意味着从故事中省略了重要但消极的统计数据;相反,研究人员应该认识到,将第一民族的结果与非土著澳大利亚人的结果进行比较的叙述是错误的,并且应该寻求只比较与研究背景绝对相关的结果。无相关披露。
{"title":"Defining the gap, emphasising the deficit","authors":"Bridie Mulholland","doi":"10.5694/mja2.52518","DOIUrl":"10.5694/mja2.52518","url":null,"abstract":"<p><span>To the Editor:</span> The Australian National Agreement on Closing the Gap is an undeniably important piece of political infrastructure.<span><sup>1</sup></span> The new approach, outlined in the 2020 National Agreement, vows to achieve First Nations equity by recognising the strength of, and empowering, First Nations people, communities and organisations.</p><p>By its nature, “closing the gap” inadvertently places non-Indigenous Australians above First Nations people and sets outcomes of non-Indigenous Australians as the gold standard. Although it is important to understand the relative and disproportionate disadvantage that First Nations people experience in Australia, the closing the gap narrative continues to perpetuate deficit discourse and encourages the benchmarking of First Nations outcomes against non-Indigenous Australians.</p><p>This deficit-driven process of benchmarking has become increasingly prevalent in First Nations-focused research, where the research problem is often described by the relative gap between First Nations people and non-Indigenous Australians. In many cases, highlighting the gap provides little value to the research, and only persists to promote deficit discourse — by continually defining the gap, we continually emphasise the deficit.</p><p>Progress towards equity for First Nations people has been slow, stunted and non-existent in many of the Closing the Gap target and priority reform areas.<span><sup>2</sup></span> In light of this, the importance of moving away from the deficit narrative surrounding First Nations outcomes is being increasingly recognised.<span><sup>3</sup></span> Driving high quality research in genuine partnership with First Nations people is key to driving real change. As such, it is critical that researchers, reviewers and journals play their part in shifting the deficit narrative.</p><p>Defining the research problem is integral to effective dissemination of research findings and attraction of funding. For health research, this often means defining rates of disease morbidity and mortality. These statistics are seldom positive but provide important context to research studies. Shifting the deficit narrative in First Nations health research should not mean that important, but negative, statistics are omitted from the story; rather, researchers should remain cognisant of the deficit narrative that comparison of First Nations outcomes to non-Indigenous Australians perpetuates, and should seek to only compare outcomes where it is absolutely pertinent to the context of the study.</p><p>No relevant disclosures.</p>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 11","pages":"631-632"},"PeriodicalIF":6.7,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52518","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inequity of access to voluntary assisted dying for New Zealand citizens residing permanently in Australia 永久居住在澳大利亚的新西兰公民在获得自愿协助死亡方面的不平等。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-06 DOI: 10.5694/mja2.52519
Christopher J Barlow

To the Editor: Recently, I had the privilege of providing end-of-life care for a remarkable man who had contributed a great richness to the cultural life of Australia. A New Zealander by birth, he came to Australia as a young man and over the subsequent four decades, built a life in Victoria. He had witnessed both good and bad deaths; a brother had died uncomfortably following an aspiration, whereas his mother had “a beautiful dying”, her suffering eased with a morphine infusion. We shared a wonderful conversation as this articulate and thoughtful man reflected on these deaths and how they guided his thoughts as he considered his own. He valued both his dignity and the impact that the manner of his death would have on those he would leave behind, and had sought out assisted dying so that he could die on his own terms.

Voluntary assisted dying (VAD) involves medical assistance to end life when the suffering from a terminal disease becomes intolerable. In Victoria,1 South Australia2 and Western Australia,3 eligibility for VAD is restricted to Australian citizens and permanent residents.4 The intended purpose of this restriction is to prevent patients travelling to access VAD.5 However, the consequence of this legislative language is to deny access to New Zealanders who have substantive connection to Australia, and who otherwise enjoy many of the rights and obligations of Australian citizens. New Zealand citizens are entitled to live, work and freely access most government benefits (including Medicare) in Australia, and so may choose to not apply for citizenship. As of 2023, there were 598 000 New Zealanders residing in Australia,6 many of whom are not eligible for VAD by circumstances of their Australian residency alone. If they remained in New Zealand, they would be entitled to access VAD there.7

This was the case for my patient, who discovered his ineligibility too late in his disease process. Although palliative care gave him a relatively quick and comfortable death, it did not give him a death on his own terms. Although I recognise the value of preventing medical tourism for the purpose of VAD, the current requirement is unnecessarily restrictive and the law, as it stands in Victoria, is unjust. The more nuanced approach taken in other states, which requires three years of residency, would remedy this inequity.

The family of the patient reviewed this letter and provided written consent for publication.

No relevant disclosures.

致编辑:最近,我有幸为一位杰出的人提供临终关怀,他为澳大利亚的文化生活做出了巨大的贡献。他出生在新西兰,年轻时来到澳大利亚,在随后的四十年里,在维多利亚州建立了自己的生活。他目睹了好的和坏的死亡;一个兄弟因误吸而痛苦地死去,而他的母亲则“美丽地死去”,她的痛苦在注射吗啡后得到缓解。我们进行了一场精彩的对话,这位口齿清晰、深思熟虑的人反思了这些死亡,以及这些死亡如何引导他思考自己的问题。他既重视自己的尊严,也重视他的死亡方式对他身后的人的影响,并寻求协助死亡,这样他就可以按照自己的方式死去。自愿协助死亡(VAD)是指当身患绝症的人无法忍受时,通过医疗援助来结束生命。在维多利亚州、南澳大利亚州和西澳大利亚州,VAD的资格仅限于澳大利亚公民和永久居民这一限制的预期目的是防止患者前往访问vad。5然而,这种立法语言的后果是拒绝与澳大利亚有实质性联系的新西兰人进入,并且他们在其他方面享有澳大利亚公民的许多权利和义务。新西兰公民有权在澳大利亚生活、工作和自由享受大多数政府福利(包括医疗保险),因此可以选择不申请公民身份。截至2023年,有59.8万新西兰人居住在澳大利亚,6其中许多人仅仅因为在澳大利亚居住而没有资格获得VAD。如果他们留在新西兰,他们将有权获得那里的VAD。我的病人就是这种情况,他在发病过程中发现自己的残疾太晚了。虽然姑息治疗让他相对迅速而舒适地死去,但它并没有让他按照自己的意愿死去。虽然我认识到以VAD为目的防止医疗旅游的价值,但目前的要求是不必要的限制,而且维多利亚州的法律是不公正的。其他州采取了更为细致的方法,要求居住三年,这将弥补这种不平等。患者家属审阅了这封信,并提供了发表的书面同意。无相关披露。
{"title":"Inequity of access to voluntary assisted dying for New Zealand citizens residing permanently in Australia","authors":"Christopher J Barlow","doi":"10.5694/mja2.52519","DOIUrl":"10.5694/mja2.52519","url":null,"abstract":"<p><span>To the Editor:</span> Recently, I had the privilege of providing end-of-life care for a remarkable man who had contributed a great richness to the cultural life of Australia. A New Zealander by birth, he came to Australia as a young man and over the subsequent four decades, built a life in Victoria. He had witnessed both good and bad deaths; a brother had died uncomfortably following an aspiration, whereas his mother had “a beautiful dying”, her suffering eased with a morphine infusion. We shared a wonderful conversation as this articulate and thoughtful man reflected on these deaths and how they guided his thoughts as he considered his own. He valued both his dignity and the impact that the manner of his death would have on those he would leave behind, and had sought out assisted dying so that he could die on his own terms.</p><p>Voluntary assisted dying (VAD) involves medical assistance to end life when the suffering from a terminal disease becomes intolerable. In Victoria,<span><sup>1</sup></span> South Australia<span><sup>2</sup></span> and Western Australia,<span><sup>3</sup></span> eligibility for VAD is restricted to Australian citizens and permanent residents.<span><sup>4</sup></span> The intended purpose of this restriction is to prevent patients travelling to access VAD.<span><sup>5</sup></span> However, the consequence of this legislative language is to deny access to New Zealanders who have substantive connection to Australia, and who otherwise enjoy many of the rights and obligations of Australian citizens. New Zealand citizens are entitled to live, work and freely access most government benefits (including Medicare) in Australia, and so may choose to not apply for citizenship. As of 2023, there were 598 000 New Zealanders residing in Australia,<span><sup>6</sup></span> many of whom are not eligible for VAD by circumstances of their Australian residency alone. If they remained in New Zealand, they would be entitled to access VAD there.<span><sup>7</sup></span></p><p>This was the case for my patient, who discovered his ineligibility too late in his disease process. Although palliative care gave him a relatively quick and comfortable death, it did not give him a death on his own terms. Although I recognise the value of preventing medical tourism for the purpose of VAD, the current requirement is unnecessarily restrictive and the law, as it stands in Victoria, is unjust. The more nuanced approach taken in other states, which requires three years of residency, would remedy this inequity.</p><p>The family of the patient reviewed this letter and provided written consent for publication.</p><p>No relevant disclosures.</p>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 11","pages":"631"},"PeriodicalIF":6.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52519","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond acute infection: mechanisms underlying post-acute sequelae of COVID-19 (PASC) 超越急性感染:COVID-19(PASC)急性后遗症的机制。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-03 DOI: 10.5694/mja2.52456
Anurag Adhikari, Janesha Maddumage, Emily M Eriksson, Sarah J Annesley, Victoria A Lawson, Vanessa L Bryant, Stephanie Gras

免疫失调是 2019 年冠状病毒病急性后遗症(PASC)(也称为长 COVID)的一个关键方面,免疫细胞持续激活、T 细胞衰竭、B 细胞特征偏差和免疫通讯紊乱从而导致与自身免疫相关的并发症。肠道正在成为微生物群、新陈代谢和整体功能障碍之间的关键环节,可能与其他慢性疲劳病症和 PASC 有相似之处。免疫血栓和神经信号系统功能障碍强调了在严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)感染的情况下,免疫系统、血液凝固和中枢神经系统之间复杂的相互作用。在设计 PASC 研究方面存在明显的研究空白,尤其是在纵向研究方面,这是一个值得关注的重要领域。
{"title":"Beyond acute infection: mechanisms underlying post-acute sequelae of COVID-19 (PASC)","authors":"Anurag Adhikari,&nbsp;Janesha Maddumage,&nbsp;Emily M Eriksson,&nbsp;Sarah J Annesley,&nbsp;Victoria A Lawson,&nbsp;Vanessa L Bryant,&nbsp;Stephanie Gras","doi":"10.5694/mja2.52456","DOIUrl":"10.5694/mja2.52456","url":null,"abstract":"<p>\u0000 \u0000 </p>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 S9","pages":"S40-S48"},"PeriodicalIF":6.7,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52456","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The crux of modern health care challenges 现代医疗挑战的症结所在。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-03 DOI: 10.5694/mja2.52488
Michael Skilton
<p>In rock climbing, the crux is the hardest section, or sections, of a particular climbing route. To solve a crux, the climber must draw on their skill and expertise, problem-solving abilities, perseverance and teamwork, before being able to send it — solve the crux and complete the route. This issue of the <i>MJA</i> covers a broad range of subjects that could be considered some of the most critical challenges in modern health and health care.</p><p>Over the past 55 years, the proportion of people in Australia who die from cardiovascular diseases has halved (https://www.abs.gov.au/statistics/health/causes-death/changing-patterns-mortality-australia/latest-release). Nonetheless, cardiovascular diseases remain a leading cause of death and morbidity. In this issue of the <i>MJA</i>, Figtree and colleagues (https://doi.org/10.5694/mja2.52482) describe the Cardiovascular Health Leadership Research Forum. Established in 2022, this initiative unites governments, health service providers, and the research workforce to tackle major cardiovascular health challenges. By accelerating the implementation of new preventive and therapeutic strategies, it seeks to enhance patient outcomes and produce economic benefits.</p><p>On a broader scale, Jackson (https://doi.org/10.5694/mja2.52476) discusses the National Health Reform Agreement, and the challenges it faces to remain fit-for-purpose for maintaining a high quality equitable health system. Seven policy barriers are identified that have long undermined health system reform, and will need to be addressed for the next agreement to be successful.</p><p>Four further articles discuss key aspects of modern socially responsible health care. Rodda and colleagues (https://doi.org/10.5694/mja2.52471) review current approaches to identifying and managing gambling disorder. Formerly known as pathological gambling, gambling disorder is now classified as a behavioural addiction. Gambling disorder affects only 1% of the population; however, gambling is pervasive in Australian culture with significant costs. Approximately three-quarters of the Australian adult population spent money on gambling in 2022, with total losses of $20–25 billion per year (https://www.aihw.gov.au/reports/australias-welfare/gambling). This does not account for the further social costs of gambling, which are extensive. Of those Australian adults who gamble, almost half are classified as being at risk of harm, with the highest rates in young people and men. The evidence base outlined by Rodda and colleagues provides best practices for identifying gambling disorder and risk thereof, and subsequent treatment.</p><p>Slape and colleagues (https://doi.org/10.5694/mja2.52475) provide a perspective on the establishment of a First Nations custodial dermatology service. This First Nations-led service, established in New South Wales and now extended to the Northern Territory, reflects a commitment to ethical and socially responsible health care services through
在攀岩运动中,"十字路口 "是某条攀岩路线中最难的一段或几段。要解决一个难点,攀岩者必须利用他们的技能和专业知识、解决问题的能力、毅力和团队合作精神,然后才能将其送出--解决难点并完成攀岩路线。本期MJA杂志涉及的主题非常广泛,可以说是现代健康和医疗保健领域最严峻的挑战之一。在过去的55年中,澳大利亚死于心血管疾病的人口比例减少了一半 (https://www.abs.gov.au/statistics/health/causes-death/changing-patterns-mortality-australia/latest-release)。然而,心血管疾病仍然是导致死亡和发病的主要原因。在本期的《医学期刊》上,Figtree及其同事(https://doi.org/10.5694/mja2.52482)介绍了心血管健康领导研究论坛(Cardiovascular Health Leadership Research Forum)。该论坛成立于 2022 年,旨在联合各国政府、医疗服务提供商和研究人员,共同应对心血管健康领域的重大挑战。通过加快实施新的预防和治疗策略,该论坛旨在提高患者的治疗效果并产生经济效益。在更广泛的范围内,杰克逊(https://doi.org/10.5694/mja2.52476)讨论了《国家卫生改革协议》,以及该协议在维持高质量的公平医疗体系方面所面临的挑战。文章指出了长期以来阻碍医疗系统改革的七大政策障碍,要使下一份协议取得成功,就必须解决这些障碍。另有四篇文章讨论了现代社会责任医疗保健的主要方面。Rodda 及其同事 (https://doi.org/10.5694/mja2.52471) 回顾了当前识别和管理赌博障碍的方法。赌博障碍以前被称为病态赌博,现在被归类为行为成瘾。赌博障碍只影响到1%的人口;然而,赌博在澳大利亚文化中无处不在,造成了巨大的损失。2022 年,约四分之三的澳大利亚成年人在赌博上花钱,每年的总损失达 200-250 亿澳元(https://www.aihw.gov.au/reports/australias-welfare/gambling)。这还不包括赌博造成的更大社会成本。在参与赌博的澳大利亚成年人中,几乎有一半被归类为面临伤害风险,其中年轻人和男性的比例最高。罗达及其同事概述的证据基础提供了识别赌博障碍及其风险以及后续治疗的最佳做法。斯莱普及其同事(https://doi.org/10.5694/mja2.52475)提供了建立原住民监护皮肤病服务的视角。这项由原住民主导的服务在新南威尔士州建立,现已扩展到北部地区,体现了通过提供及时、优质、文化上安全的医疗保健服务,满足被监禁者复杂的医疗保健需求,提供符合道德规范、对社会负责的医疗保健服务的承诺。更广泛地说,这项服务的基本原则凸显了在监狱系统内由原住民主导的专科医疗服务的前景。诺兰及其同事(https://doi.org/10.5694/mja2.52471)在研究信中使用了药品福利计划(PBS)中的去身份化配药数据,证明尽管药品福利计划中没有明确的性别确认适应症,但每五个药品福利计划补贴的睾酮处方中就有一个是为变性人开的。在年轻人中,这一数字高达五分之四。他们认为,针对 "性别确认 "的特定 PBS 授权指示将有助于变性人公平地获得医疗服务并提高医疗质量。最后,Fry 及其同事的医学教育文章(https://doi.org/10.5694/mja2.52481),用他们的话说,"旨在作为环境足迹技术的入门介绍,可用于揭示医疗服务对环境的影响",并明确将重点放在温室气体排放上。他们指出了五个关键的行动领域,包括提高医疗环境足迹知识,将环境足迹纳入现有的质量改进、采购和医疗系统绩效框架。这些切实可行的建议不仅对医护人员的个人实践有影响,也许更重要的是,对卫生和医疗领导及管理部门引导的系统变革也有影响。这些都是现代卫生和医疗保健领域最具挑战性的一些方面。就像登山者在峭壁上攀登一样,这些挑战需要医疗和卫生保健界的共同努力,才能为患者和更广泛的社区带来最佳结果。
{"title":"The crux of modern health care challenges","authors":"Michael Skilton","doi":"10.5694/mja2.52488","DOIUrl":"10.5694/mja2.52488","url":null,"abstract":"&lt;p&gt;In rock climbing, the crux is the hardest section, or sections, of a particular climbing route. To solve a crux, the climber must draw on their skill and expertise, problem-solving abilities, perseverance and teamwork, before being able to send it — solve the crux and complete the route. This issue of the &lt;i&gt;MJA&lt;/i&gt; covers a broad range of subjects that could be considered some of the most critical challenges in modern health and health care.&lt;/p&gt;&lt;p&gt;Over the past 55 years, the proportion of people in Australia who die from cardiovascular diseases has halved (https://www.abs.gov.au/statistics/health/causes-death/changing-patterns-mortality-australia/latest-release). Nonetheless, cardiovascular diseases remain a leading cause of death and morbidity. In this issue of the &lt;i&gt;MJA&lt;/i&gt;, Figtree and colleagues (https://doi.org/10.5694/mja2.52482) describe the Cardiovascular Health Leadership Research Forum. Established in 2022, this initiative unites governments, health service providers, and the research workforce to tackle major cardiovascular health challenges. By accelerating the implementation of new preventive and therapeutic strategies, it seeks to enhance patient outcomes and produce economic benefits.&lt;/p&gt;&lt;p&gt;On a broader scale, Jackson (https://doi.org/10.5694/mja2.52476) discusses the National Health Reform Agreement, and the challenges it faces to remain fit-for-purpose for maintaining a high quality equitable health system. Seven policy barriers are identified that have long undermined health system reform, and will need to be addressed for the next agreement to be successful.&lt;/p&gt;&lt;p&gt;Four further articles discuss key aspects of modern socially responsible health care. Rodda and colleagues (https://doi.org/10.5694/mja2.52471) review current approaches to identifying and managing gambling disorder. Formerly known as pathological gambling, gambling disorder is now classified as a behavioural addiction. Gambling disorder affects only 1% of the population; however, gambling is pervasive in Australian culture with significant costs. Approximately three-quarters of the Australian adult population spent money on gambling in 2022, with total losses of $20–25 billion per year (https://www.aihw.gov.au/reports/australias-welfare/gambling). This does not account for the further social costs of gambling, which are extensive. Of those Australian adults who gamble, almost half are classified as being at risk of harm, with the highest rates in young people and men. The evidence base outlined by Rodda and colleagues provides best practices for identifying gambling disorder and risk thereof, and subsequent treatment.&lt;/p&gt;&lt;p&gt;Slape and colleagues (https://doi.org/10.5694/mja2.52475) provide a perspective on the establishment of a First Nations custodial dermatology service. This First Nations-led service, established in New South Wales and now extended to the Northern Territory, reflects a commitment to ethical and socially responsible health care services through","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 9","pages":"451"},"PeriodicalIF":6.7,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52488","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An allied health model of care for long COVID rehabilitation 针对长期 COVID 康复的联合医疗模式。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-03 DOI: 10.5694/mja2.52457
Joanne M Wrench, Leigh R Seidel Marks
<p>Although the acute disease burden of coronavirus disease 2019 (COVID-19) in Australia has reduced, the longer term impacts are becoming increasingly apparent.<span><sup>1</sup></span> The constellation of persistent symptoms is termed “post-acute COVID-19 condition”, also known as “long COVID”, and includes dyspnoea, fatigue, cognitive impairments, headaches, and psychiatric symptoms.<span><sup>2, 3</sup></span> The health impact at a population level is significant, with between 10% and 20% of people having persistent symptoms after a COVID-19 infection.<span><sup>4, 5</sup></span></p><p>Patient testimonies describe the devastating impact of symptoms left untreated by health services.<span><sup>6, 7</sup></span> The functional sequalae of long COVID include reduced quality of life<span><sup>8, 9</sup></span> and difficulty engaging in normal life roles, including family, work and caring responsibilities.<span><sup>10</sup></span> COVID-19 has also disproportionately affected disadvantaged communities who have less access to health care services and less resources to allow for absences from work.<span><sup>11</sup></span></p><p>As the world has returned to normal, many people living with long COVID continue to report feeling left behind and isolated by persistent symptoms.<span><sup>12</sup></span> Alongside this, many people report feeling ignored or not believed by health care providers, who often struggle to pinpoint physiological impairment and associated treatments.<span><sup>13</sup></span> This can lead to a marked discordance between the lived experience of ongoing debilitation and the expectations of the community and health care sector of what recovery from COVID-19 looks like.</p><p>Initially, Australia's response to long COVID followed a specialist clinic model of care, including individual referrals to respiratory and cardiac specialists. With the emergence of milder acute illness, the model of care for long COVID in Australia has now moved to primary care, with general practitioners seen as the coordinators of ongoing services and interventions.<span><sup>14</sup></span></p><p>The heterogeneous nature of long COVID symptoms, coupled with no diagnostic tool or single treatment, means the functional burden of long COVID may best be addressed by symptom management approaches.<span><sup>15, 16</sup></span> In this regard, Australian and international guidelines recommend multidisciplinary and coordinated allied health care as a practice standard for people with long COVID,<span><sup>17, 18</sup></span> and there is emerging evidence of corresponding functional improvement.<span><sup>19, 20</sup></span> In line with these recommendations, the National Health Service in the United Kingdom encourages a three-tiered approach to care, with multidisciplinary interventions offered to people with the most severe symptoms requiring input from two or more professionals, stepping down to community therapy teams, and then self-management pathway
最常见的中重度症状是疲劳、脑雾和心理影响(方框 3)。大多数接受服务的参与者都接受过不止一名多学科团队成员的诊治(63%)。运动生理学是需求量最大的学科,其次是临床心理学和职业疗法(方框 4)。我们的 "失访 "率很低,仅为 7%。个人学科治疗辅以在线自我管理资源22 和定制的虚拟小组项目,共有 72 人参加。长期慢性阻塞性肺气肿干预措施的证据基础正在形成,干预措施以临床指南为基础,如美国国家卫生保健与卓越研究所指南17,这些指南目前主要处于专家共识或低证据水平。根据这些指南,门诊干预措施包括:(i) 一站式协调护理方法;(ii) 对疲劳、脑雾、嗅觉障碍、睡眠和声音变化进行管理;(iii) 临床心理支持和干预,包括对持续症状的适应、持续的 COVID-19 和健康焦虑、一般心理障碍以及病前心理健康问题的加重;(iv) 与高血压专科医疗服务机构合作,对体位性正位性心动过速综合征进行调查、诊断和管理;以及 (v) 职业治疗支持功能改善,使患者能够重新参与重要的活动和生活角色,如工作和照顾他人的责任。澳大利亚为长期慢性心力衰竭患者提供建议的多学科护理的公共卫生服务仍然相对较少。大多数人都无法获得康复服务,而这些服务可以缓解症状、改善生活质量并帮助他们重新扮演有价值的生活角色。ReCOVery 护理模式是根据国际指南开发的,为参与者提供了有影响力的护理。否则,接受我们服务的人很有可能会被我们的医疗系统拒之门外,无法获得传统的伤后或急性康复服务或老年护理服务。ReCOVery 模式为支持患者的阶梯式护理方法提供了可行的蓝图,并通过我们的使用数据为联合医疗学科的需求提供了初步证据。尽管如此,维多利亚州多家公立长期 COVID 诊所的服务资金已基本停止。这加剧了谁能获得医疗服务的不公平,大多数人根本无法负担私人专职医疗服务。获得联合医疗服务的护理计划可由全科医师完成,但只能提供五次治疗,缺口费也很常见。我们几乎只能通过远程医疗来有效运行 ReCOVery 服务。长 COVID 中心远程医疗中心是一种可行的模式,可为最需要的人提供治疗。这种远程医疗模式支持大多数澳大利亚人难以获得的专科治疗,如临床神经心理学。我们认识到,来自不同文化和语言背景以及弱势社区的人可能无法随时使用远程医疗基础设施,因此有些人需要选择以中心为基础的服务。分层(阶梯)治疗是管理长期 COVID 最有效、最具成本效益的方法,已在其他地方成功实施。通过全科医生的评估和转诊来简化流程可能会缓解这一就医障碍。16 尽管全科医生完全有能力成为患者的主要医疗联系人,但他们仍需要通过专职医疗人员进行治疗干预方面的教育和转诊选择。多学科康复治疗是改善有严重持续症状的患者的生活质量、减轻全科医生负担的最有效解决方案。不幸的是,在澳大利亚,除非我们通过公共卫生服务或医疗保险回扣来增加获取机会,否则这种机会将仅限于经济条件较好的人。墨尔本大学通过澳大利亚大学图书馆员理事会达成了 Wiley - 墨尔本大学协议,该协议的一部分就是墨尔本大学提供的开放获取出版服务。
{"title":"An allied health model of care for long COVID rehabilitation","authors":"Joanne M Wrench,&nbsp;Leigh R Seidel Marks","doi":"10.5694/mja2.52457","DOIUrl":"10.5694/mja2.52457","url":null,"abstract":"&lt;p&gt;Although the acute disease burden of coronavirus disease 2019 (COVID-19) in Australia has reduced, the longer term impacts are becoming increasingly apparent.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The constellation of persistent symptoms is termed “post-acute COVID-19 condition”, also known as “long COVID”, and includes dyspnoea, fatigue, cognitive impairments, headaches, and psychiatric symptoms.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; The health impact at a population level is significant, with between 10% and 20% of people having persistent symptoms after a COVID-19 infection.&lt;span&gt;&lt;sup&gt;4, 5&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Patient testimonies describe the devastating impact of symptoms left untreated by health services.&lt;span&gt;&lt;sup&gt;6, 7&lt;/sup&gt;&lt;/span&gt; The functional sequalae of long COVID include reduced quality of life&lt;span&gt;&lt;sup&gt;8, 9&lt;/sup&gt;&lt;/span&gt; and difficulty engaging in normal life roles, including family, work and caring responsibilities.&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt; COVID-19 has also disproportionately affected disadvantaged communities who have less access to health care services and less resources to allow for absences from work.&lt;span&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;As the world has returned to normal, many people living with long COVID continue to report feeling left behind and isolated by persistent symptoms.&lt;span&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/span&gt; Alongside this, many people report feeling ignored or not believed by health care providers, who often struggle to pinpoint physiological impairment and associated treatments.&lt;span&gt;&lt;sup&gt;13&lt;/sup&gt;&lt;/span&gt; This can lead to a marked discordance between the lived experience of ongoing debilitation and the expectations of the community and health care sector of what recovery from COVID-19 looks like.&lt;/p&gt;&lt;p&gt;Initially, Australia's response to long COVID followed a specialist clinic model of care, including individual referrals to respiratory and cardiac specialists. With the emergence of milder acute illness, the model of care for long COVID in Australia has now moved to primary care, with general practitioners seen as the coordinators of ongoing services and interventions.&lt;span&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The heterogeneous nature of long COVID symptoms, coupled with no diagnostic tool or single treatment, means the functional burden of long COVID may best be addressed by symptom management approaches.&lt;span&gt;&lt;sup&gt;15, 16&lt;/sup&gt;&lt;/span&gt; In this regard, Australian and international guidelines recommend multidisciplinary and coordinated allied health care as a practice standard for people with long COVID,&lt;span&gt;&lt;sup&gt;17, 18&lt;/sup&gt;&lt;/span&gt; and there is emerging evidence of corresponding functional improvement.&lt;span&gt;&lt;sup&gt;19, 20&lt;/sup&gt;&lt;/span&gt; In line with these recommendations, the National Health Service in the United Kingdom encourages a three-tiered approach to care, with multidisciplinary interventions offered to people with the most severe symptoms requiring input from two or more professionals, stepping down to community therapy teams, and then self-management pathway","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 S9","pages":"S5-S9"},"PeriodicalIF":6.7,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52457","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical Journal of Australia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1